Sio Capital Management
Latest statistics and disclosures from Sio Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MMS, CELC, SNY, DNTH, ALKS, and represent 40.32% of Sio Capital Management's stock portfolio.
- Added to shares of these 10 stocks: CELC (+$39M), ALKS (+$20M), SNY (+$18M), HSIC (+$15M), KVUE (+$14M), DNTH (+$13M), GSK (+$12M), HAE (+$9.7M), KALV (+$8.3M), CRNX (+$7.3M).
- Started 15 new stock positions in NVCR, SLP, KALV, CRNX, TFX, RAPP, Shoulder Innovations, KVUE, HSIC, ALKS. Bridgebio Oncology Therapeut, Nextcure, HAE, GSK, CELC.
- Reduced shares in these 10 stocks: DRUG (-$20M), GMED (-$15M), , ANNX (-$9.8M), , SEPN (-$7.4M), ANIP (-$5.2M), AORT, TYRA, EWTX.
- Sold out of its positions in ATYR, ALEC, ANNX, ATXS, AVNS, AORT, EMBC, ENTA, GMED, IDXX. INMB, MBX, NBIX, NXTC, TVTX, MRUS.
- Sio Capital Management was a net buyer of stock by $73M.
- Sio Capital Management has $395M in assets under management (AUM), dropping by 50.91%.
- Central Index Key (CIK): 0001482416
Tip: Access up to 7 years of quarterly data
Positions held by Sio Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Sio Capital Management
Sio Capital Management holds 51 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Maximus (MMS) | 12.9 | $51M | 558k | 91.37 |
|
|
| Celcuity (CELC) | 9.8 | $39M | NEW | 787k | 49.40 |
|
| Sanofi Sa Sponsored Adr (SNY) | 6.7 | $27M | +200% | 563k | 47.20 |
|
| Dianthus Therapeutics (DNTH) | 5.8 | $23M | +144% | 578k | 39.35 |
|
| Alkermes SHS (ALKS) | 5.1 | $20M | NEW | 675k | 30.00 |
|
| Disc Medicine (IRON) | 4.8 | $19M | 285k | 66.08 |
|
|
| Merck & Co (MRK) | 3.8 | $15M | 177k | 83.93 |
|
|
| Henry Schein (HSIC) | 3.7 | $15M | NEW | 219k | 66.37 |
|
| Centene Corporation (CNC) | 3.5 | $14M | +47% | 388k | 35.68 |
|
| Kenvue (KVUE) | 3.5 | $14M | NEW | 844k | 16.23 |
|
| BioMarin Pharmaceutical (BMRN) | 3.1 | $12M | 225k | 54.16 |
|
|
| GSK Sponsored Adr (GSK) | 2.9 | $12M | NEW | 269k | 43.16 |
|
| Bright Minds Biosciences Com New (DRUG) | 2.9 | $12M | -62% | 191k | 60.66 |
|
| Haemonetics Corporation (HAE) | 2.4 | $9.7M | NEW | 198k | 48.74 |
|
| Aquestive Therapeutics (AQST) | 2.1 | $8.4M | +58% | 1.5M | 5.59 |
|
| Kalvista Pharmaceuticals (KALV) | 2.1 | $8.3M | NEW | 684k | 12.18 |
|
| Anteris Technologies Global (AVR) | 2.0 | $8.0M | -3% | 1.8M | 4.50 |
|
| Crinetics Pharmaceuticals In (CRNX) | 1.8 | $7.3M | NEW | 175k | 41.65 |
|
| Tyra Biosciences (TYRA) | 1.8 | $7.2M | -36% | 515k | 13.99 |
|
| Rapport Therapeutics (RAPP) | 1.4 | $5.5M | NEW | 185k | 29.70 |
|
| Novocure Ord Shs (NVCR) | 1.4 | $5.3M | NEW | 414k | 12.92 |
|
| Biosante Pharmaceuticals (ANIP) | 1.3 | $5.1M | -50% | 56k | 91.60 |
|
| Edgewise Therapeutics (EWTX) | 1.3 | $5.0M | -43% | 307k | 16.22 |
|
| Teleflex Incorporated (TFX) | 1.2 | $4.9M | NEW | 40k | 122.36 |
|
| Simulations Plus (SLP) | 1.2 | $4.8M | NEW | 320k | 15.07 |
|
| Proqr Therapeutics N V Shs Euro (PRQR) | 1.1 | $4.4M | 2.1M | 2.13 |
|
|
| Shoulder Innovations Common Stock | 1.1 | $4.4M | NEW | 350k | 12.55 |
|
| Pmv Pharmaceuticals (PMVP) | 0.9 | $3.7M | -29% | 2.6M | 1.40 |
|
| Septerna (SEPN) | 0.9 | $3.6M | -67% | 189k | 18.81 |
|
| Ideaya Biosciences (IDYA) | 0.9 | $3.4M | 124k | 27.21 |
|
|
| Aligos Therapeutics Com New (ALGS) | 0.8 | $3.3M | 336k | 9.80 |
|
|
| Erasca (ERAS) | 0.8 | $3.0M | 1.4M | 2.18 |
|
|
| Vir Biotechnology (VIR) | 0.7 | $2.7M | 478k | 5.71 |
|
|
| Savara (SVRA) | 0.7 | $2.6M | 727k | 3.57 |
|
|
| Ventyx Biosciences (VTYX) | 0.7 | $2.6M | -36% | 829k | 3.11 |
|
| Neuroone Med Technologies Com New (NMTC) | 0.5 | $2.1M | -33% | 2.4M | 0.89 |
|
| Ovid Therapeutics (OVID) | 0.5 | $1.9M | -36% | 1.4M | 1.30 |
|
| Bridgebio Oncology Therapeut Com New | 0.4 | $1.5M | NEW | 131k | 11.58 |
|
| Context Therapeutics (CNTX) | 0.3 | $1.3M | 1.3M | 0.97 |
|
|
| Senseonics Hldgs (SENS) | 0.3 | $1.0M | -52% | 2.3M | 0.44 |
|
| Tela Bio (TELA) | 0.2 | $948k | 636k | 1.49 |
|
|
| Avalo Therapeutics Com New (AVTX) | 0.2 | $917k | 72k | 12.71 |
|
|
| Foghorn Therapeutics (FHTX) | 0.2 | $601k | 123k | 4.89 |
|
|
| Modular Med Com New (MODD) | 0.1 | $550k | 786k | 0.70 |
|
|
| Nyxoah S A SHS (NYXH) | 0.1 | $234k | 51k | 4.60 |
|
|
| Boundless Bio (BOLD) | 0.1 | $201k | 164k | 1.23 |
|
|
| Aprea Therapeutics Com New (APRE) | 0.0 | $166k | -59% | 112k | 1.48 |
|
| Terns Pharmaceuticals (TERN) | 0.0 | $76k | 10k | 7.51 |
|
|
| Nextcure Com New | 0.0 | $64k | NEW | 11k | 5.86 |
|
| Rocket Pharmaceuticals *w Exp 09/02/202 (RCKTW) | 0.0 | $14k | 400k | 0.04 |
|
|
| Humacyte *w Exp 08/27/202 (HUMAW) | 0.0 | $12k | 50k | 0.24 |
|
Past Filings by Sio Capital Management
SEC 13F filings are viewable for Sio Capital Management going back to 2010
- Sio Capital Management 2025 Q3 filed Nov. 13, 2025
- Sio Capital Management 2025 Q2 filed Aug. 13, 2025
- Sio Capital Management 2025 Q1 filed May 15, 2025
- Sio Capital Management 2024 Q4 filed Feb. 14, 2025
- Sio Capital Management 2024 Q3 filed Nov. 14, 2024
- Sio Capital Management 2024 Q2 filed Aug. 14, 2024
- Sio Capital Management 2024 Q1 filed May 15, 2024
- Sio Capital Management 2023 Q3 filed Nov. 14, 2023
- Sio Capital Management 2023 Q2 filed Aug. 14, 2023
- Sio Capital Management 2023 Q1 filed May 12, 2023
- Sio Capital Management 2022 Q4 filed Feb. 13, 2023
- Sio Capital Management 2022 Q3 filed Nov. 14, 2022
- Sio Capital Management 2022 Q2 filed Aug. 15, 2022
- Sio Capital Management 2022 Q1 filed May 16, 2022
- Sio Capital Management 2021 Q4 filed Feb. 14, 2022
- Sio Capital Management 2021 Q3 filed Nov. 15, 2021